New Atlas5h
"100% successful" cancer drug gets landmark FDA approval
Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration ...
Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...
Multiple Sclerosis News Today4d
Tolebrutinib for SPMS granted FDA breakthrough therapy designation
Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...
FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...
Hosted on MSN28m
Finding Hope: A Paralyzed Woman’s Journey with an FDA-Approved Breakthrough Treatment
Life can change in the blink of an eye. For Alix Schneider, this reality struck during a routine day when an unpredict ...
Gilead granted Breakthrough Therapy Designation for Trodelvy by FDA
Gilead (GILD) announced that the FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with ...
Breakthrough in blood cancer treatment: AIIMS researchers develop promising CAR T-cell therapy for multiple myeloma
AIIMS researchers claim to have made significant progress in developing chimeric antigen receptor (CAR) T-cell therapy, ...
Targeted Oncology4d
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...
Zacks.com on MSN3d
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...
Targeted Oncology3d
FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC
The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...